SITE014-0233

SITE014 (NLD) › SITE014-0233

SITE014-0233

A Phase III, Randomized, Double-Blind Study of Torivumab Plus Chemotherapy Versus Placebo Plus Chemotherapy in Previously Untreated Advanced Non-Small Cell Lung Cancer · Phase III
SITE014 (NLD) · Dr. Moreau
consented 2026-06-08

enrolled

AEs

1

Serious

0

Dropout signal

–

Adverse events

1

Grade 1 Neutropenia — outcome: RECOVERED/RESOLVED; onset 2023-01-19 (study day 37); relationship: RELATED

mild assessed

Data queries

0

No data queries. Open queries would appear here for this patient.